Lincoln Pharmaceuticals posts Q2 FY24 consolidated PAT at Rs. 27.65 Cr

Lincoln Pharmaceuticals has reported total income of Rs. 164.68 crores during the period ended September 30, 2023

Lincoln Pharmaceuticals posts Q1 FY24 standalone net profit at Rs. 19.01 Cr

Lincoln Pharmaceuticals posts FY23 PAT at Rs. 72.90 Cr

For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year

Lincoln Pharmaceuticals Q1 FY23 consolidated profit up at Rs. 15.01 Cr

The company has reported total income of Rs. 129.96 crores during the period ended June 30, 2022.

Lincoln Pharma gets Australian TGA approval

The company plans to expand its portfolio in regulated markets aggressively

Lincoln Pharma plans to launch Cephalosporin product portfolio soon

Cephalosporin is a bactericidal, broad-spectrum, and P-lactam antibiotic originally derived from the fungus Acremonium, which is used to treat bacterial infections such as pneumonia, skin infections, ear infection, strep throat, staph infections, tonsillitis, bronchitis among others

NCLT approves amalgamation of Lincoln Parenteral with Lincoln Pharma

The amalgamation is expected to bring in a lot of synergies in terms of operational efficiency and productivity for the combined entity

Lincoln consolidated Q4FY21 net profit at Rs. 12.57 Cr

The company plans to enter the EU markets in FY22

Promoters of Lincoln Pharma increases holding by 4.9%

The promoter holding in the company has increased to 37.25%, a rise of 4.9% from 32.35% as of 31 March 2020